MedTrace Logo

Mefloquine Prophylaxis in HIV-1 Individuals: a Randomized Placebo-controlled Trial

NCT00373048 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2011-05-24

No results posted yet for this study

Summary

This is a randomized placebo controlled trial. Malaria chemoprophylaxis with mefloquine in asymptomatic HIV-infected adults living in a malaria endemic region of Luanshya, Zambia will be compared to a placebo control group and followed up for 18 months.

Conditions

  • HIV Infections

Interventions

DRUG

mefloquine

tablet, once weekly

DRUG

placebo

tablet, once weekly

Sponsors & Collaborators

  • Institute of Tropical Medicine, Belgium

    lead OTHER

Principal Investigators

  • Umberto D'Alessandro, MD,MSc, PHD · Institute of Tropical Medicine Antwerp

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2007-12-31
Completion
2011-05-31

Countries

  • Zambia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00373048 on ClinicalTrials.gov